Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs NetFlix Inc (NFLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs NetFlix Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while NetFlix Inc trades at $73.9 (market cap $308.95B). The key difference: NetFlix Inc is far larger — about 7.7× Alnylam Pharmaceuticals, Inc.'s market cap. Which is the better fit depends on your goals.
| ALNY | NFLX | |
|---|---|---|
Market Cap | $39.89B | $308.95B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $127.42 |
52-Week Low | $278.09 | $70.91 |
Enterprise Value | $38.15B | $311.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Netflix (NFLX) trades at $73.37, down 2.78% on the day, reflecting recent bearish momentum despite strong fundamentals. The stock shows robust revenue growth, with 2025 revenue reaching $45.18 billion and net income at $10.98 billion, while technical indicators signal near-term weakness. Analyst sentiment remains positive with a consensus price target of $111.80, though recent news highlights concerns over its losing streak and competitive pressures in the streaming sector.
The outlook for NFLX is mixed; strong profitability and expanding ad revenue offer upside, but technical bearishness and market volatility pose risks. Investors should weigh solid fundamentals against near-term price pressure, with analyst consensus suggesting significant potential appreciation if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About NetFlix Inc
Netflix Inc. is an Internet subscription service for watching television shows and movies. Subscribers can instantly watch unlimited television shows and movies streamed over the Internet to their televisions, computers, and mobile devices and in the United States, subscribers can receive standard definition DVDs and Blu-ray Discs delivered to their homes.
Read more on NFLX →
